• Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX Kalkine Fri, 10 Jul 2026 13:22:00 GMT
• stocktake: alterity receives $4m r&d tax boost ahead of pivotal phase iii msa trial The Cairns Post Fri, 10 Jul 2026 02:16:08 GMT
• Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government Moomoo Thu, 09 Jul 2026 10:58:37 GMT
• [6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K Stock Titan Thu, 09 Jul 2026 10:42:29 GMT
• Alterity Therapeutics (NASDAQ: ATHE) receives A$3.98m R&D tax refund Stock Titan Thu, 09 Jul 2026 10:03:36 GMT
• Alterity Therapeutics Announces Quotation of New Securities Following Option Conversion Kalkine Thu, 09 Jul 2026 01:59:12 GMT
• Alterity Therapeutics (ATH) Lists 76,191 New Shares on ASX Following Option Conversion Kalkine Media Wed, 08 Jul 2026 15:59:12 GMT
• Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy Moomoo Tue, 07 Jul 2026 14:43:06 GMT
• Alterity Therapeutics aligns with FDA on Phase 3 neurology drug path grafa.com Tue, 07 Jul 2026 14:14:00 GMT
• Alterity Therapeutics Limited Receives FDA End-Of-Phase 2 Meeting Minutes Confirming Registrational Pathway For ATH434 In Multiple... marketscreener.com Tue, 07 Jul 2026 12:57:45 GMT
• Alterity Therapeutics (ATHE) Advances Towards Phase 3 Trial Appr GuruFocus Tue, 07 Jul 2026 12:06:37 GMT
• Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System ... Yahoo Finance Tue, 07 Jul 2026 11:05:00 GMT
• FDA backs single Phase 3 trial for Alterity’s MSA drug ATH434 Stock Titan Tue, 07 Jul 2026 11:05:00 GMT
• Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4% Moomoo Tue, 07 Jul 2026 02:36:03 GMT
• Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway Yahoo Finance Australia Tue, 07 Jul 2026 02:16:00 GMT
• Alterity Therapeutics Secures FDA Pathway for Phase 3 Trial of ATH434 in MSA Kalkine Tue, 07 Jul 2026 00:12:20 GMT
• alterity therapeutics clears key fda hurdle for ath434 phase 3 pathway Proactive financial news Mon, 06 Jul 2026 07:00:00 GMT
• Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery Revenue Breakdown – ASX:ATHDB TradingView Sun, 05 Jul 2026 21:42:07 GMT
• Alterity Therapeutics Ltd Warrant 2025-26.02.27 on Alterity Thera Financial Disclosures & Filings TradingView Wed, 01 Jul 2026 22:37:32 GMT
• [6-k] alterity therapeutics ltd current report (foreign issuer) | athe sec filing - form 6-k Stock Titan Wed, 01 Jul 2026 10:06:27 GMT
• Alterity Therapeutics Converts 4,105 Options into Ordinary Shares at $0.50 Each Kalkine Wed, 01 Jul 2026 07:52:31 GMT
• ATHE Initiated Coverage by Jones Trading -- Price Target Announced at $16.00 GuruFocus Tue, 30 Jun 2026 15:23:11 GMT
• [6-k] alterity therapeutics ltd current report (foreign issuer) | athe sec filing - form 6-k Stock Titan Tue, 30 Jun 2026 10:32:31 GMT
• Jones Trading initiates Alterity Therapeutics stock with buy rating By Investing.com Investing.com Nigeria Mon, 29 Jun 2026 07:00:00 GMT
• alterity therapeutics ltd. actuals & estimates (asx:ath) TradingView Sat, 27 Jun 2026 20:08:52 GMT
• price to earnings forward of alterity therapeutics ltd. – asx:ath TradingView Sat, 27 Jun 2026 06:57:44 GMT
• alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery TradingView Fri, 26 Jun 2026 21:04:49 GMT
• alteriry therapeutics ltd sponsored adr actuals & estimates (nasdaq:athe) TradingView Fri, 26 Jun 2026 14:36:20 GMT
• price to sales forward of alterity therapeutics limited – otc:prnad TradingView Fri, 26 Jun 2026 10:05:34 GMT
• equity in earnings of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Fri, 26 Jun 2026 05:02:13 GMT
• Alterity Therapeutics Ltd. Actuals & Estimates (ASX:ATH) TradingView Thu, 25 Jun 2026 19:33:54 GMT
• alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery TradingView Tue, 23 Jun 2026 23:10:25 GMT
• Director at Alterity (NASDAQ: ATHE) receives 2M options grant Stock Titan Tue, 23 Jun 2026 07:00:00 GMT
• Director of ALTERITY THERAPEUTICS (ATHE) granted 1,000,000 listed options at $1.00 Stock Titan Tue, 23 Jun 2026 07:00:00 GMT
• alterity therapeutics ltd (athe) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? Yahoo Finance Fri, 19 Jun 2026 07:00:00 GMT
• ASX: ATH — Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise Kalkine Thu, 18 Jun 2026 07:00:00 GMT
• alterity therapeutics ltd (athe) dividends & stock splits: historical payouts and event timeline TradingKey Thu, 18 Jun 2026 05:57:07 GMT
• alterity therapeutics ltd (athe) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Thu, 18 Jun 2026 02:53:02 GMT
• alterity therapeutics ltd (athe) shareholder structure: major shareholders & institutional holdings TradingKey Thu, 18 Jun 2026 02:22:27 GMT
• alterity therapeutics ltd (athe) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 15:21:16 GMT
• alterity therapeutics ltd (athe) risk assessment: volatility, financial risk & investment risk TradingKey Wed, 17 Jun 2026 15:20:00 GMT
• alterity therapeutics ltd (athe) institutional confidence TradingKey Wed, 17 Jun 2026 15:19:54 GMT
• alterity therapeutics ltd (athe) financial health: profitability & balance sheet analysis TradingKey Wed, 17 Jun 2026 15:19:28 GMT
• alterity therapeutics ltd (athe) earnings forecast: future eps & revenue growth estimates TradingKey Wed, 17 Jun 2026 15:19:27 GMT
• alterity therapeutics ltd (athe) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 17 Jun 2026 14:55:26 GMT
• alterity therapeutics files june 2026 corporate presentation with u.s. regulator The Globe and Mail Wed, 17 Jun 2026 10:32:00 GMT
• [6-k] alterity therapeutics ltd current report (foreign issuer) | athe sec filing - form 6-k Stock Titan Wed, 17 Jun 2026 10:05:09 GMT
• alterity therapeutics (athe) surges over 10%: key levels in focus - put dominated dars.gov.et Wed, 17 Jun 2026 07:00:00 GMT
• alterity, fda agree on phase 3 program for multiple system atrophy asset ath434 MSN Tue, 16 Jun 2026 10:15:01 GMT
• [6-k] alterity therapeutics ltd current report (foreign issuer) | athe sec filing - form 6-k Stock Titan Tue, 16 Jun 2026 10:08:38 GMT
• Here's Why We're Not Too Worried About Alterity Therapeutics' (ASX:ATH) Cash Burn Situation simplywall.st Tue, 16 Jun 2026 07:00:00 GMT
• alterity therapeutics: target price consensus and analysts recommendations | ath | au0000043945 marketscreener.com Mon, 15 Jun 2026 19:38:19 GMT
• alterity therapeutics: dividend historical data and projections marketscreener.com Mon, 15 Jun 2026 19:38:14 GMT
• [6-k] alterity therapeutics ltd current report (foreign issuer) | athe sec filing - form 6-k Stock Titan Mon, 15 Jun 2026 10:12:47 GMT
• prnad sec filings - alterity therapeutics ltd 10-k, 10-q, 8-k forms Stock Titan Mon, 15 Jun 2026 10:12:46 GMT
• Alterity Therapeutics Issues 3 Million Unquoted Options at $1.00 Exercise Price, Expiring June 2031 Kalkine Mon, 15 Jun 2026 07:00:00 GMT
• Alterity Therapeutics Discloses Lapse of 360,000 Options as Conditions Remain Unmet Kalkine Mon, 15 Jun 2026 07:00:00 GMT
• alterity therapeutics completes 50-for-1 capital consolidation after shareholder approval The Globe and Mail Sat, 13 Jun 2026 07:00:00 GMT
• 50-for-1 reverse split reshapes Alterity (NASDAQ: ATHE) capital base Stock Titan Fri, 12 Jun 2026 07:00:00 GMT
• Kalkine Stock Analysis: Are Investors Reassessing Alterity Therapeutics' Clinical Pipeline? Kalkine Fri, 12 Jun 2026 07:00:00 GMT
• analysts offer insights on healthcare companies: alterity therapeutics (otherprnad) and nuvalent (nuvl) The Globe and Mail Fri, 12 Jun 2026 07:00:00 GMT
• alterity, fda agree on phase 3 program for multiple system atrophy asset ath434 MSN Thu, 11 Jun 2026 17:41:59 GMT
• alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery TradingView Thu, 11 Jun 2026 09:31:55 GMT
• gross margin % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 09:31:50 GMT
• price to cash flow ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 09:31:46 GMT
• ebit per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 09:31:42 GMT
• gross profit of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 09:31:18 GMT
• asset turnover of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 09:05:14 GMT
• pretax income of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 09:03:49 GMT
• total debt per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 08:57:29 GMT
• debt to assets ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 08:57:25 GMT
• book value per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 08:57:25 GMT
• ebit of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 08:57:03 GMT
• net income of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 08:41:21 GMT
• ebit of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 07:55:09 GMT
• operating income of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 07:38:19 GMT
• free cash flow of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 07:36:50 GMT
• price to sales ratio of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 07:35:53 GMT
• ebitda margin % of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 07:35:50 GMT
• taxes of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 07:25:17 GMT
• discontinued operations of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 07:25:03 GMT
• cost of goods sold of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 07:10:05 GMT
• ebitda of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:51:35 GMT
• cash per share of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:50:24 GMT
• quick ratio of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:50:09 GMT
• net margin % of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:48:56 GMT
• enterprise value of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:48:26 GMT
• free float of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:43:30 GMT
• alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery TradingView Thu, 11 Jun 2026 06:41:46 GMT
• inventory turnover of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:40:43 GMT
• taxes of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:37:13 GMT
• total equity of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 06:35:45 GMT
• total revenue of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 05:59:52 GMT
• net debt of alterity therapeutics ltd warrant 2025-26.02.27 on alterity thera/deferred delivery – asx:athdc TradingView Thu, 11 Jun 2026 05:59:26 GMT
• capex per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 05:24:10 GMT
• ebitda of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 05:23:58 GMT
• total assets of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 05:04:20 GMT
• total liabilities of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Thu, 11 Jun 2026 05:02:09 GMT
• return on assets % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 23:29:39 GMT
• free float of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 23:28:27 GMT
• alterity therapeutics advances lead drug towards pivotal study for rare neuromuscular disorder Sahm Wed, 10 Jun 2026 22:04:20 GMT
• operating margin % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 20:39:59 GMT
• total debt of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 19:08:25 GMT
• pretax income of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:20:26 GMT
• cash per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:20:24 GMT
• total revenue of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:09:45 GMT
• revenue per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:07:29 GMT
• EBITDA per share of Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery – ASX:ATHDB TradingView Wed, 10 Jun 2026 14:07:25 GMT
• enterprise value of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:07:01 GMT
• price to earnings ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:06:52 GMT
• price to sales ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:06:14 GMT
• ebitda margin % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:06:03 GMT
• free cash flow per share of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:05:59 GMT
• return on equity % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:02:41 GMT
• dilution adjustment of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:02:29 GMT
• asset turnover of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:01:39 GMT
• current ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 14:01:21 GMT
• net margin % of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 13:51:51 GMT
• number of shareholders of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 13:35:27 GMT
• quick ratio of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 13:35:06 GMT
• inventory turnover of alterity therapeutics ltd warrant 2023-31.08.26 on alterity/deferred delivery – asx:athdb TradingView Wed, 10 Jun 2026 13:25:36 GMT
• Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery Statistics – ASX:ATHDB TradingView Wed, 10 Jun 2026 13:14:36 GMT
• alterity, fda agree on phase 3 program for multiple system atrophy asset ath434 MSN Wed, 10 Jun 2026 03:22:09 GMT
• alterity therapeutics (athe) gets fda nod for phase 3 program GuruFocus Tue, 09 Jun 2026 23:45:28 GMT
• alterity therapeutics (athe) secures fda agreement for phase 3 a GuruFocus Tue, 09 Jun 2026 15:26:02 GMT
• fda backs alterity (nasdaq: athe) ath434 phase 3 plan in msa Stock Titan Tue, 09 Jun 2026 10:00:53 GMT
• Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Yahoo Finance Tue, 09 Jun 2026 07:00:00 GMT
• MSA drug that slowed decline 48% gets FDA nod for Phase 3 plan Stock Titan Tue, 09 Jun 2026 07:00:00 GMT
• Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder Benzinga Tue, 09 Jun 2026 07:00:00 GMT
• Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434 Seeking Alpha Tue, 09 Jun 2026 07:00:00 GMT
• US drug regulator backs Alterity’s pivotal phase III trial The Australian Tue, 09 Jun 2026 07:00:00 GMT
• Alterity gains FDA alignment to advance ATH434 Phase 3 in multiple system atrophy BiotechDispatch Tue, 09 Jun 2026 07:00:00 GMT
• Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434 Kalkine Tue, 09 Jun 2026 07:00:00 GMT
• Alterity secures FDA alignment on pivotal Phase 3 trial for MSA drug grafa.com Tue, 09 Jun 2026 07:00:00 GMT
• Alterity Therapeutics (ASX:ATH) Shares Surge 19%: What's Driving Interest? Kalkine Tue, 09 Jun 2026 07:00:00 GMT
• alterity therapeutics reaches us fda alignment on phase three trial for neurodegenerative disorder treatment candidate Moomoo Tue, 09 Jun 2026 07:00:00 GMT
Alterity Therapeutics Limited(NASDAQ:ATHE) 
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It i...
Website: http://www.alteritytherapeutics.com
Founded: 1997
CEO: David Stamler
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends